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Luciferases have been applied extensively as convenient and powerful reporting 
tools in numerous biomedical researches.1, 2). These enzymes oxidize the substrates 
leading to emission of bioluminescence, which can be observed visually using a charge-
coupled device camera or measured quantitatively using a luminometer.2, 3) In the past 
decade, luciferase-based bioluminescence has become indispensable for monitoring of 
biological processes including gene expression, protein-protein interactions, cell 
trafficking, tumorigenesis, and high-throughput screening assays in drug discovery4-11).  
Nano-luciferase is a novel engineered luciferase enzyme that originates from the 
deep-sea shrimp Oplophorus gracilirostris and was structural optimized by Promega12). 
This enzyme can be used as an intracellular reporter or as a secreted reporter when it is 
appended with a secretion signal from human interleukin 612). This engineered luciferase 
enzyme is monomeric and maintains high enzyme stability both inside living cells and 
in culture medium, with longer half-life12, 13). It utilizes a coelenterazine or furimazine, 
a coelenterazine analog, as substrates to produce a glow-type luminescence12). The 
luminescent signal produced by Nano-luciferase is approximately 150-fold brighter than 
those produced by firefly or Renilla luciferases, which have been extensively applied in 
biomedical studies13). These advantages make Nano-luciferase an attractive tool as a 
reporter for bioluminescence assays. Nowadays Nano-luciferase has already been used 
to generate a wide variety of transgenic organisms and cells for in vivo and in vitro 
studies14-18). 
Compared with intracellular luciferases, secreted luciferases are particularly 
advantageous in many applications, such as non-invasive quantitative assessments, real-
time monitoring and high-throughput drug screening19-24). Therefore, secreted Nano-
luciferase (secNluc) can be intensively utilized as a powerful tool in these research areas. 
Although secNluc has characteristics of high stability, long half-life and high signal 
intensity emission12), reporter system utilizing this enzyme have several practical 
application limitations25). For example, similar to other secreted luciferases, secNluc 
makes an inevitable coexistence with some interfering components such as serum and 
residual experimental reagents in conditioned medium surrounding test cells or in 
biological samples such as blood or urine25, 26). Additionally, the signal intensity may 
not exceed the background interferences in some special circumstances, such as low cell 
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density. In Chapter 1, a simple affinity purification strategy was developed to separate 
secNluc from culture medium to avoid interferences from serum or residual reagents. 
Meanwhile, the strategy could greatly enhance the signal intensity via secNluc 
enrichment, and enhance the stability of the reaction kinetic curve by transferring the 
luciferase to an optimal environment. This strategy may contribute to biomedical studies 
utilizing secNluc and other secreted luciferases, especially those requiring superior 
sensitivity, low background noise and high reproducibility. 
Herbal medicine has been reported to exhibit various pharmacological effects, 
including the prevention of tumor progression by inhibiting cell proliferation and tumor 
promotion27). Many of extracts are the predominant chemical components of the 
essential oil derived from medicinal herbs and possess therapeutic properties such as 
anti-inflammatory, antioxidant, analgesic, and antitumorigenic activities28). According 
to the previous researches, the Traditional Chinese Medicine Extract Library has been 
applied for studying monomers with potential antineoplastic activity. Besides, the study 
is available to discover new unreported antitumor components. Meanwhile, the 
mechanism of components was expounded to provide new research ideas for Traditional 
Chinese Medicine to inhibit cancer. It has been reported28-30) that to inhibit nuclear 
factor kappa B (NF-κB) activation was considered to be an effective and positive effect 
in antitumor research. Therefore, the NF-κB transcription factor reporter gene system 
has been constructed for screening potential drugs. And it may help to discover the novel 
antitumor reagents by the perspective. In the present study, two monomers, p-cymene 
and shikonin, were found from Traditional Chinese Medicine Extract Library using 
secNluc reporter system, which shown ability to inhibit NF-κB activation. Subsequently, 
antineoplastic activity of the two monomers was examined in vitro. The NF-κB 
transcription factor reporter system contained the NF-κB-TATA-Box, which promoter 
means the expression of reporter gene was regulated only by NF-κB stimulation. It can 
ensure the accuracy of the further study. 
The proteolytic degradation of extracellular matrix (ECM) components in basement 
membranes and stroma tissues is requisite for progressing the invasion and metastasis 
of malignant tumor cells. Matrix metalloproteinases (MMPs) play a crucial role in ECM 
degradation, and different sets of MMPs concertedly act in ECM breakdown31, 32). 
Gelatinase A (72-kDa type IV collagenase)/MMP-2 and gelatinase B (92-kDa type IV 
collagenase)/MMP-9 have been reported to facilitate tumor cell invasion and epithelial-
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mesenchymal transition as a promoter and/or modulator in normal and tumor cells in 
vivo and in vitro33). On the other hand, the enzymic activity of MMPs and proteolytic 
activation of the MMP precursor (proMMP) have been reported to be controlled by 
endogenous inhibitors such as tissue inhibitors of metalloproteinases (TIMPs) 34). Since 
four TIMPs have been identified, designated as TIMP-1, TIMP-2, TIMP-3, and TIMP-
4, they inhibit MMPs by forming a strong noncovalent complex with a 1:1 
stoichiometry34). Regarding the inhibitory properties among the TIMPs, TIMPs can bind 
to different sets of MMPs: e.g., the preference inhibition of TIMP-1 against MMP-9, 
MMP-3, and MMP-1, and that of TIMP-2 against MMP-2 rather than MMP-934, 35). 
Therefore, the inhibition of expression and/or enzymic activity of MMP is likely to be 
an effective target(s) for prevent constructing tumor invasion and metastasis31, 32). 
The p-cymene (4-isopropyltoluene) is a natural monoterpene hydrocarbon in the 
essential oil from the resin of Protium species36) and the root of Angelica archangelica37). 
In addition, it has been reported that the extract of Angelica archangelica inhibits the 
growth of mouse breast cancer cells in vivo and in vitro38). On the other hand, herbal 
medicine-derived terpenoids have been reported to exhibit not only antiproliferative but 
also antiinvasive activity against tumor cells in vivo and in vitro28). Several studies have 
shown that triptolide, a diterpenoid triepoxide, exhibits the inhibitory activity against 
both the proliferation and invasion of tumor cells in vivo and in vitro39-41). However, it 
remains to clarify that p-cymene has antitumor invasive activity.  
     Shikonin, a natural compound isolated from the Chinese herbal plant 
Lithospermum Erythrorhizon, has been applied extensively for thousands of years for 
the treatment of diverse diseases. Shikonin has been recently demonstrated to have 
tumoricidal42, 43) and antiproliferative44, 45) abilities, to reverse drug resistance to 
chemotherapy46-48) and to enhance the cytotoxicity of chemotherapy47-49). On the other 
hand, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising 
antitumor drug, because it can induce apoptosis in cancer cells, while causing minimal 
cytotoxicity in normal cells50, 51). Since an intrinsic or acquired resistance to TRAIL-
induced apoptosis has limited its further utilization in clinical trials52), reagents that can 
sensitize resistant cancer cells to TRAIL-induced apoptosis may be requisite for novel 
cancer therapy. In this regard, it has been shown that shikonin mimics the 
antitumorigenic action of TRAIL, whereas there is little cytotoxicity in normal cells43, 
46, 53). However, it remains unclear whether shikonin sensitizes TRAIL-resistant tumor 
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cells to TRAIL-induced cytotoxicity, and whether a cotreatment with shikonin and 
TRAIL causes cytotoxicity in normal cells.  
In the present study, I have demonstrated secreted Nano-luciferase (secNluc) 
reporter system using affinity purification strategy was developed for screening new 
antineoplastic reagents such as p-cymene and shikonin from Chinese herbal extracts 
(Chapter 1). Furthermore, Chapters 2 and 3, p-cymene and shikonin were characterized 




Optimized Application of Secreted Nano-Luciferase Reporter System 
Using Affinity Purification Strategy 
 
1.1 INTRODUCTION 
Nano-luciferase provides considerable luminescent signal than traditional 
luciferases which previously reported. However, secNluc was influenced inevitably by 
various factors such as serum and residual experimental reagents, which exist in 
conditioned medium surrounding test cells or in biological samples26, 54). Additionally, 
the signal intensity may not be above the limit of detection in experiments with low cell 
density. In the present chapter, a simple affinity purification strategy was developed to 
separate secNluc from culture medium to negate interferences from serum or residual 
reagents. Meanwhile this strategy could greatly increase the signal intensity via secNluc 
enrichment and enhance the stability of the reaction kinetic curve by transferring the 
luciferase to an optimal environment. 
 
1.2 MATERIALS AND METHODS 
1.2.1 Plasmid construction 
The DNA sequences encoding secNluc and secNluc-FLAG, shown in Table 1.1 
(GenBank accession number MG009448), were synthesized by the PolePolar 
Biotechnology Co. Ltd (Beijing, China) and cloned into the EcoR I and Sal I sites of the 
pDC316-EBNA vector, a generous gift from the laboratory of Dr. Bin Gao (Institute of 
Microbiology, CAS, China) and the Age I and EcoR I sites of the pQCXIP vector 
individually. The DNA sequence encoding NF-κB enhancer and TATA box (NF-κB-
TATA box), shown in Table 1, was also synthesized by the PolePolar Biotechnology Co. 
Ltd (Beijing, China), and was cloned into the Bgl II and Age I sites of the constructed 
pQCXIP-secNluc-FLAG vector to replace the original MCMV promoter sequence. All 
constructed plasmids were confirmed by DNA sequencing. 
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1.2.2 Cell transfection and protein preparation 
HEK-293E cells were purchased from National Infrastructure of Cell Line Resource, 
China. GP2-293 cells were purchased from Clontech. The passage numbers of these two 
cells are both less than 30. HeLa cells were purchased from the American Type Culture 
Collection (ATCC, USA). HEK-293E cells were grown as suspension cultures in CD293 
medium (GIBCOTM, Thermo Fisher Scientific Inc, USA) supplemented with 1% 
GlutaMAX (100×) (Life Technologies, USA). The cells were routinely maintained at 
exponential phase in 125-ml shaker flasks, which were agitated at 120 rpm in a 
humidified, 5% CO2 and water-jacketed incubator at 37˚C. The PEI-mediated 
transfection of HEK-293E cells with the constructed pDC316-EBNA-secNluc plasmid 
was performed according to a previously report55). The culture medium was 
concentrated by ultrafiltration, dialyzed against phosphate-buffered saline (PBS, pH7.4) 
and then subjected to size-exclusion chromatography (Superdex 75, GE Healthcare Life 
Sciences, USA). The protein was collected from the peak corresponding to 
approximately 13 ml and analyzed by 12% SDS-PAGE. GP2-293 and HeLa cells were 
cultured in a humidified incubator (5% CO2 in air) at 37˚C, and maintained in DMEM 
containing 10% (v/v) heat-inactivated FBS. GP2-293 cells were transfected with the 
constructed pQCXIP-NF-κB-secNluc-FLAG plasmid using lipofectamine 2000 (Life 
Technologies, USA) according to the manufacturer’s protocol. Cell culture medium 
containing secreted luciferase was collected for further analyses. A helper plasmid, 
pVSV-G, was co-transfected with the constructed pQCXIP-NF-κB-secNluc-FLAG 
plasmid into GP2-293 cells for the preparation of retroviruses. The retroviruses were 
used to infect HeLa cells according to the manufacturer’s protocol (Clontech, USA). 
After selected by puromycin (4μg/ml) (Sigma, USA), a monoclonal cell line stably 
expressing secNluc-FLAG was chosen for the TNF-α stimulation analysis experiment. 
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Table 1.1 Sequences of the NF-κB-TATA box, secNluc and secNluc-FLAG. (NF-κB-enhancer-
TATA Box: BglⅡis 1 to 6; Age I is 237 to 242. secNluc-FLAG: Age I is 1 to 6; secNluc is 7 to 
610; FLAG-Taq is 611 to 652; Terminator is 653 to 655; EcoR I is 656 to 661. 
Sequence Name Serial No Sequence (GenBank accession number MG009448) 
NF-κB-enhancer-TATA Box 1 AGATCTGGGA ATTTCCGGGA ATTTCCGGGA ATTTCCGGGA ATTTCCTTAA 
TTAAAGACTC TAGAGGGTAT ATAATGGAGC CAATGACAAG ACGCTGGGCG 
 
101 GGGTTTGTGT CATCATAGAA CTAAAGACAT GCAAATATAT TTCTTCCGGG 
GACACCGCCA GCAAACGCGA GCAACGGGCC ACGGGGATGA AGCAGCGAAG 
 
201 AAATCTGCAC TCGACGGTAG CGCGGGACCG GCATCCACCG GT 
secNluc 1 ACCGGTCGCC ACCATGAACT CCTTCTCCAC AAGCGCCTTC GGTCCAGTTG 
CCTTCTCCCT GGGCCTGCTC CTGGTGTTGC CTGCTGCCTT CCCTGCCCCA 
secNluc-FLAG 1 ACCGGTCGCC ACCATGAACT CCTTCTCCAC AAGCGCCTTC GGTCCAGTTG 
CCTTCTCCCT GGGCCTGCTC CTGGTGTTGC CTGCTGCCTT CCCTGCCCCA 
secNluc 101 GTCTTCACAC TCGAAGATTT CGTTGGGGAC TGGCGACAGA CAGCCGGCTA 
CAACCTGGAC CAAGTCCTTG AACAGGGAGG TGTGTCCAGT TTGTTTCAGA 
secNluc-FLAG 101 GTCTTCACAC TCGAAGATTT CGTTGGGGAC TGGCGACAGA CAGCCGGCTA 
CAACCTGGAC CAAGTCCTTG AACAGGGAGG TGTGTCCAGT TTGTTTCAGA 
secNluc 201 ATCTCGGGGT GTCCGTAACT CCGATCCAAA GGATTGTCCT GAGCGGTGAA 
AATGGGCTGA AGATCGACAT CCATGTCATC ATCCCGTATG AAGGTCTGAG 
secNluc-FLAG 201 ATCTCGGGGT GTCCGTAACT CCGATCCAAA GGATTGTCCT GAGCGGTGAA 
AATGGGCTGA AGATCGACAT CCATGTCATC ATCCCGTATG AAGGTCTGAG 
secNluc 301 CGGCGACCAA ATGGGCCAGA TCGAAAAAAT TTTTAAGGTG GTGTACCCTG 
TGGATGATCA TCACTTTAAG GTGATCCTGC ACTATGGCAC ACTGGTAATC 
secNluc-FLAG 301 CGGCGACCAA ATGGGCCAGA TCGAAAAAAT TTTTAAGGTG GTGTACCCTG 
TGGATGATCA TCACTTTAAG GTGATCCTGC ACTATGGCAC ACTGGTAATC 
secNluc 401 GACGGGGTTA CGCCGAACAT GATCGACTAT TTCGGACGGC CGTATGAAGG 
CATCGCCGTG TTCGACGGCA AAAAGATCAC TGTAACAGGG ACCCTGTGGA 
secNluc-FLAG 401 GACGGGGTTA CGCCGAACAT GATCGACTAT TTCGGACGGC CGTATGAAGG 
CATCGCCGTG TTCGACGGCA AAAAGATCAC TGTAACAGGG ACCCTGTGGA 
secNluc 501 ACGGCAACAA AATTATCGAC GAGCGCCTGA TCAACCCCGA CGGCTCCCTG 
CTGTTCCGAG TAACCATCAA CGGAGTGACC GGCTGGCGGC TGTGCGAACG 
secNluc-FLAG 501 ACGGCAACAA AATTATCGAC GAGCGCCTGA TCAACCCCGA CGGCTCCCTG 
CTGTTCCGAG TAACCATCAA CGGAGTGACC GGCTGGCGGC TGTGCGAACG 
secNluc 601 CATTCTGGCG TAAGAATT C 
secNluc-FLAG 601 CATTCTGGCG ACGCGTGCCG GTGATTACAA GGATGACGAT GATAAGGCCG 
GTTAAGAATT C 
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1.2.3 Effects of pH, FBS and residual reagents on secNluc-catalyzed 
bioluminescence reactions 
The DMEM and RPMI1640 pH values were adjusted to a series of values ranging 
from 5.0 to 9.0 in increments of 0.5. The prepared secNluc protein at a final 
concentration of 20 ng/ml and the substrate coelenterazine at a final concentration of 3 
μmol/L were added to the modified media, and the final volume of each sample was 
100 μl. Emitted bioluminescence was measured in 96-well plates using a Biotek 
Synergy 2 Multi-Mode Plate Reader (Biotek, USA) after the addition of substrate. To 
test the influence of FBS, secNluc at final concentrations ranging from 0 to 1000 pg/ml 
and the substrate coelenterazine at a final concentration of 3 μmol/L were added to 
phosphate-buffered saline (PBS pH7.4) containing 0 to 10% (v/v) FBS in a total volume 
of 100 μl per well. Emitted bioluminescence was measured as described above. To test 
the influence of residual reagents, six Chinese herbal monomers, geniposide, 
ligustrazine, glycyrrhizic acid, p-cymene, shikonin and puerarin were random selected 
from Traditional Chinese Medicine Extract Library (Herbpurify, China), dissolved in 
DMSO at 5 mg/ml as 100× stock solutions, and 1μl of each stock solution was diluted 
in 100 μl of PBS (pH 7.4) containing 20 ng/ml secNluc and 3 μmol/L coelenterazine 
for analysis. DMSO (1 μl) was used as the control. To test whether the influence existed 
after the secNluc was added FLAG-Taq, DMEM was adjusted to designated pH value 
as 6.5, 7.5 and 8.5. Both of the final concentration of secNluc and secNluc-FLAG was 
20 ng/ml. The concentration of substrate coelenterazine, besides all items of testing 
parameters and equipment was used under the uniform conditions with pH value 5.0 -
9.0. The glycyrrhizic acid and puerarin were also used to evaluate the influence of 
FLAG-tag on the enzymatic activity of secNluc. Dissolution method and concentration 
of drug monomer, secNluc protein and secNluc-FLAG protein were performed as 
mentioned above. Emitted bioluminescence was measured as described above. 
1.2.4 Optimal buffer for secNluc-catalyzed bioluminescence reactions 
SecNluc at a final concentration of 5 ng/ml and the substrate coelenterazine at a 
final concentration of 3 μmol/L were added to 6 different buffers: DMEM, RPMI1640, 
DMEM containing 10% (v/v) heat-inactivated FBS (D10), RPMI1640 containing 10% 
(v/v) heat-inactivated FBS (R10), Phosphate-Buffered Saline (PBS), and PBS 
containing 0.03% (v/v) Triton X-100 (PBST). Emitted bioluminescence at the various 
time points was measured as described above. 
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1.2.5 Purification of secNluc-FLAG using magnetic beads 
At 24h or 48h after transfection with the constructed pQCXIP- NF-κB-secNluc-
FLAG plasmid, GP2-293 cell culture medium from dishes, 24-well plates or 96-well 
plates were transferred to either sterilized tubes or new 96-well plates according to the 
reaction volume. Different amounts of M2 anti-FLAG magnetic beads (Sigma) (2.5 μl 
of beads for 100 μl, 2 ml or 5 ml of medium; and 10 μl of beads for 2 ml or 5 ml of 
medium) were added to the media, and the mixtures were incubated at room 
temperature for 10 minutes in a rotary mixer at 30 rpm (for tubes) or in a shaker 
incubator at 100 rpm (for 96-well plates). The magnetic beads were then attracted and 
immobilized by a magnet and the supernatants were removed by pipettes. The 
immobilized beads were washed with PBST and collected by magnets twice before 
being resuspended in 100 μl of PBST. For 96-well plates, resuspended solutions were 
directly subjected to the spectrometer after the addition of 3 μmol/L coelenterazine and 
the enzyme-catalyzed bioluminescence was measured as described above. For tubes, 
resuspended solutions were transferred to new 96-well plates and the bioluminescence 
measurement was performed as described above. 
1.2.6 Comparison of secNluc-catalyzed bioluminescence between systems with or 
without purification 
Briefly, at 24 h after transfection with the constructed pQCXIP- NF-κB-secNluc-
FLAG plasmid, 20 μl of GP2-293 cell cultured medium was added to 100 μl of PBST 
containing 3 μmol/L coelenterazine and the emitted bioluminescence was measured as 
described above. Simultaneously, a resuspended solution prepared according to the 
described purification strategy from an equal aliquot of cell culture medium was added 
to the same reaction buffer, and the emitted bioluminescence was measured equally. 
For the detection of residual reagent removal, the manipulations were similar except 
the addition of residual reagent group, in which different concentrations of glycyrrhizic 
acid were mixed with culture medium before bioluminescence measurement or 
magnetic bead purification. 
1.2.7 TNF-α stimulation analysis 
A monoclonal HeLa cell line stably transfected with the NF-κB-secNluc-FLAG 
gene was cultured in a humidified incubator (5% CO2 in air) at 37˚C and maintained in 
DMEM containing 10% (v/v) heat-inactivated FBS. Cells were counted and inoculated 
in fresh DMEM complete medium at the designated cell densities in 24-well plates. 
Next, 50 ng/ml of TNF-α was added to induce the activation of NF-κB signaling in the 
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engineered cell line. After 12 h, 10, 50 and 100 μl of culture medium from cell cultures 
with or without TNF-α stimulation were collected and mixed with 90, 50 and 0 μl of 
PBST for bioluminescence measuring. Meanwhile, another 100 μl of culture medium 
from cell culture with or without TNF-α stimulation was collected and subjected to 
magnetic bead purification, during which the beads were resuspended in 100 μl of PBST. 
The subsequent bioluminescence measurement was performed as described above. 
1.2.8 Screening of Traditional Chinese Medicine Extract Library by NF-κB 
reporter gene system 
    Traditional Chinese Medicine Extract Library was used to study the effect on NF-
κB pathway and seek the effective drugs. A monoclonal HeLa cell line stably 
transfected with the NF-κB-secNluc-FLAG gene was cultured in a humidified 
incubator (5% CO2 in air) at 37˚C and maintained in DMEM containing 10% (v/v) heat-
inactivated FBS. Cells were counted and inoculated in fresh DMEM complete medium 
at the designated cell densities in 24-well plates. Cytotoxicity test was implemented 
according to CCK-8 kit (Dojindo, Japan). The maximum nontoxic concentration was 
selected to observe the influence on NF-κB, measurement was performed as described 
above. 
1.2.9 Statistical Analysis 
All data are expressed as the means ± standard deviations (SD) from at least three 
independent experiments. Data are analyzed by Student’s t-test; P < 0.05 was 
considered to indicate a statistically significant difference. 
 
1.3 RESULTS 
1.3.1 Effects of pH, FBS and residual reagents on secNluc-catalyzed 
bioluminescence reactions 
As a newly developed secreted luciferase, secNluc is thought to own the 
advantages of high structural stability, long half-life, and glow-type kinetics over other 
secreted luciferases including the Gaussia, Metridia and Cypridina luciferases13). 
However, whether interfering factors existing in the environment would limit its 
application since it had to be combined with these factors after secretion. To examine 
this, first prepared the purified secNluc protein. After transfecting 293E cells with the 
constructed pDC316-EBNA-secNluc plasmid, the secreted proteins in the culture 
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medium were concentrated and purified using a size-exclusion chromatography. SDS-
PAGE analysis showed that the protein collected from the size-exclusion 
chromatography peak corresponding to approximately 13 ml had a molecular weight of 
22 kDa (Figure 1-1A), which is equal to the theoretical size of secNluc. The luciferase 
activity of the purified protein was proven in subsequent experiments. 
The next examination was the effects of three factors, pH, FBS and residual 
reagents, which are the common interfering factors existing in medium surrounding test 
cells, on secNluc-catalyzed bioluminescence reactions. The results showed that pH had 
a significant influence on bioluminescence production (Figure 1-1B). The light 
intensities exhibited comparatively little variety from pH values ranging from pH 7.0 
to 8.5, with the strongest light output being observed at pH 7.5. However, when the pH 
of the medium was below 7.0 or over 8.5, the light intensity decreased rapidly. The 
result presented in Figure 1-1C showed that FBS could produce some luminescence 
signal, even in the absence of secNluc. This background signal increased as the FBS 
concentration increased and could shield the measured bioluminescence signals 
produced by secNluc-catalyzed reactions when the latter was weak. In addition, the 
Chinese herbal monomers, geniposide, ligustrazine, glycyrrhizic acid and puerarin, 
were used to mimic residual reagents. The results showed that, although geniposide had 
no influence on secNluc-catalyzed bioluminescence reactions, ligustrazine, 
glycyrrhizic acid and puerarin did have influence (Figure 1-1D). Specifically, 50 μg/ml 
glycyrrhizic acid could decrease the bioluminescence signal to approximately 40% of 
that of the control. These results indicated that factors in the medium, such as pH, FBS 
and residual reagents, might have significant effects on secNluc-catalyzed 
bioluminescence reactions and thus probably limit the applications of the secNluc 






Figure 1-1. The influence of the external environment on the secNluc. Effects of 
pH, FBS and residual reagents on secNluc-catalyzed bioluminescence reactions. (A) 
Preparation of secNluc proteins. SecNluc proteins were secreted by HEK-293E cells 
transfected with the constructed pDC316-EBNA-secNluc plasmid, purified via 
ultrafiltration concentration and size-exclusion chromatography with the Superdex 75 
column (GE Healthcare), and analyzed by 12% SDS-PAGE. Lane 1, protein marker; 
lane 2, purified protein. (B) Effects of DMEM and RPMI1640 media pH on secNluc-
catalyzed bioluminescence reactions. The assay was performed as described in the 
Materials and Methods. (C) Effects of FBS on secNluc-catalyzed bioluminescence 
reactions. The assay was performed as described in the Materials and Methods. (D) 
Effects of several Chinese herbal monomers, including geniposide, ligustrazine, 
glycyrrhizic acid, p-cymene, shikonin and puerarin on secNluc-catalyzed 
bioluminescence reactions. The reagents were used at a concentration of 50 μg/ml, and 
the assays were performed as described in the Materials and Methods. The ordinate 
values represent the ratios of RLU in the groups of Chinese herbal monomers to that in 
the control group. ** P < 0.01 and *** P < 0.001.  In (B) to (D), the data shown are 









1.3.2 PBST was used as an optimal buffer for secNluc-catalyzed bioluminescence 
reactions 
The experiment tried to find an optimal buffer for secNluc-catalyzed 
bioluminescence reactions. This optimal buffer needed to provide a stable pH and 
contribute to the production of stable glow-type light emission kinetics, which are 
important for the precision and reliability of reporter systems. Herein, six buffers were 
compared: DMEM, RPMI1640, D10, R10, PBS and PBST. The bioluminescence 
signals from the DMEM, RPMI1640, D10 and R10 groups decayed rapidly (Figure 1-
2). The relative light unit (RLU) values at the 60s time point dropped to half of their 
initial values in the DMEM and RPMI1640 groups and to 65% of their initial values in 
the D10 and R10 groups, and the signals almost fully faded after 120 s in the DMEM 
and RPMI1640 groups and after 150 s in the D10 and R10 groups. In the PBS and PBST 
groups, however, the decay rates of the bioluminescence signals were obviously slower 
than those of the other four groups (Figure 1-2). Compared between the two buffers, 
PBST provided the best performance, with less than a 10% decrease in the RLU value 
being observed at 150 s, and this buffer generally met the requirements of providing a 
stable pH and contributing to the production of stable glow-type light emission kinetics. 
PBST was selected as the optimal buffer for secNluc-catalyzed bioluminescence 
reactions. 
 
Figure 1-2. PBST was the compatible buffer. Comparison of light emission kinetics 
deduced from secNluc-catalyzed bioluminescence reactions in different buffers. In total, 
5 ng/ml secNluc and 3 μmol/L coelenterazine were added to six buffers: DMEM, 
RPMI1640, D10, R10, PBS and PBST. The emitted bioluminescence at different time 
points (0 to 270 s at an interval of 30 s) was measured after the addition of 
coelenterazine in a 96-well plate by a Biotek Synergy 2 multi-mode plate reader (Biotek, 
USA).  The data shown are the means ± SDs of three independent experiments. 
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1.3.3 A simple affinity purification strategy for optimizing secNluc reporter 
system applications 
Since interfering factors in the medium could affect secNluc-catalyzed 
bioluminescence reactions, these problems were tried to develop a method to resolve. 
Magnetic beads conjugated with an antibody against a specific protein tag could 
recognize and catch secNluc that was fused with the tag and thus separate the enzyme 
from the surrounding medium through a simple step consisting of magnet attraction and 
supernatant removal. This process could get rid of interfering factors in the medium and 
transfer secNluc into an optimal buffer, thus improving the application of the secNluc 
reporter system. Herein, a FLAG tag was fused to the C-terminus of secNluc using 
genetic construction (Figure 1-3A) and used anti-FLAG magnetic beads to carry out 
the purification strategy. 
First to examine whether the beads themselves could produce luminescence. The 
result presented in Figure 1-3B showed no differences in luminescence signals from 
samples in both the presence and absence of beads, indicating that the beads had no 
background signal. The result presented in Figure 1-3C confirmed that for 100 μl of 
media, 2.5 μl of beads could recover almost all of the secNluc-FLAG proteins. For 2 
and 5 ml of media, 10 μl of beads could recover approximately 90% and 80% of 
secNluc-FLAG proteins, respectively, and 2.5 μl of beads could recover approximately 
65% and 50% of secNluc-FLAG proteins, respectively (Figure 1-3D). This result 
indicated that secNluc-FLAG proteins could be concentrated dozens of times from 2 
and 5 ml of solution if they were put in 100 μl of solution. As proof, RLU values from 
2 ml of DMEM and RPMI1640 using 10 μl of beads were approximately 18.4-fold and 
17.5-fold higher than those from 100 μl of those media in our test, respectively (Figure 
1-3E). Notably, the recover abilities among the four media were not obviously different 
(Figure 1-3C). Subsequent examination showed that similar to the result above (Figure 
1-1C), when the medium containing secNluc-FLAG was diluted with a certain fold D10 
or R10, which represented a certain low concentration of secNluc-FLAG in medium, 
the RLU values tended to be constant due to the background FBS signal (Figure 1-3F). 
When using the purification method, however, the RLU values exhibited a significant 
linear correlation with the dilution fold till the value approached zero (the lower 
detection limit of the apparatus) (Figure 1-3F). Another test revealed a similar result as 
seen in Figure 1-3G. The RLU values in the group with beads purification had good 
linear correlation with the inoculated cell numbers throughout the entire test. In the 
group without bead purification, however, the RLU values tended to be constant due to 
the background FBS signal when the inoculated cell numbers were less than 2×103 cells 
per well in this test. In addition, the result presented in Figure 1-3H showed that the 
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bead purification method could help restore the luciferase activity of secNluc-FLAG 
that was inhibited by glycyrrhizic acid, a residual reagent mimic (Figure 1-1D). 
There was a possibility that the fused FLAG-tag in this strategy may had the 
stabilizing effect on the enzymatic activity of secNluc. Thus, the influence of FLAG-
tag was tested by using secNluc and secNluc-FLAG in this study. The results showed 
that RLU had no significant difference even though FLAG-tag existed or not at each 
pH value (Figure 1-3I), demonstrating that secNluc-catalyzed bioluminescence 
reactions was not impacted by FLAG-tag under different pH value. Furthermore, 
secNluc-FLAG did not show any stabilizing effect on secNluc-catalyzed 




















Figure 1-3. Plasmid construction and purification effect of magnetic beads. (A): 
Schematic representation of the constructed pQCXIP-NF-κB-secNluc-FLAG plasmid. 
(B): Luminescence signals induced by anti-FLAG beads. 2.5 μl of anti-FLAG beads 
were added to 100 μl of PBST containing 3 μmol/L coelenterazine to measure the 
luminescence signals induced by the beads. Additionally, 2.5 μl of beads binding 
secNluc-FLAG fusion proteins was used as the positive control, and PBST containing 
coelenterazine alone was used as the negative control. (C) and (D): Recovery of 
secNluc-FLAG proteins in different media after purification with anti-FLAG beads. 2.5 
μl of beads were mixed with 100 μl of four different media containing the secreted 
secNluc-FLAG protein (C). Similarly, 2.5 μl and 10 μl of beads were mixed with 2 ml 
and 5 ml of the four different media containing the secreted secNluc-FLAG protein (D). 
Bead isolation and bioluminescence measurements were performed as described in the 
Materials and Methods. (E): Concentration of the secNluc-FLAG protein using the 
purification strategy. 2 ml of D10 and R10 culture media were mixed with 10 μl of 
beads, and the bioluminescence values were measured from isolated beads that were 
resuspended in 100 μl of PBST (D10 with beads and R10 with beads) as described 
above. The bioluminescence values from 100 μl of the two cultured media (D10 and 
R10) were measured simultaneously. (F) and (G): Enhancement of the purification 
strategy on the linear correlation of secNluc and emitted bioluminescence. The culture 
medium containing the secreted secNluc-FLAG protein was diluted from 0- to 1024-
fold in D10 or R10 media, and 100 μl of the diluted solutions and 100 μl of the 
resuspended solutions that were obtained from the corresponding diluted solutions 
using the purification strategy were used to measure the emitted bioluminescence (F). 
2×101 to 2×105 transfected cells per well were inoculated into 24-well plates for 24 h, 
and 100 μl of the cultured media and 100 μl of the resuspended solutions obtained from 
the corresponding cultured media using the purification strategy were used to measure 
the emitted bioluminescence (G). (H): The elimination of interference from glycyrrhizic 
acid using the purification strategy. The glycyrrhizic acid at concentrations from 0 to 
100 μg/ml was added to D10 media containing the secNluc-FLAG protein. 100 μl of 
media and 100 μl of the resuspended solutions obtained from the corresponding media 
using the purification strategy were used to measure the emitted bioluminescence. (I): 
Effects of secNluc with or without FLAG-tag in different pH values on secNluc-
catalyzed bioluminescence reactions. The assay was performed as described in the 
Materials and Methods. (J): Effects of secNluc with or without FLAG-tag in different 
drug monomer on secNluc-catalyzed bioluminescence reactions.   Because of the 
extensive dilution multiple, Logarithmic calculation was employed in order to decrease 
the drift degree of data. In (B) to (J), the data shown are the means ± SDs of three 
independent experiments. 
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1.3.4 The purification strategy optimizes TNF-α-stimulated NF-κB activation 
assay - a case study 
TNF-α-stimulated NF-κB activation assay was used as a case study to examine the 
improved effects resulting from the purification strategy. The RLU values in the 
Medium group were maintained at approximately 600 units when a small number of 
inoculated cells were used (less than 4000 cells per well without TNF-α stimulation and 
less than 500 cells per well with TNF-α stimulation) (Figure 1-4A and 4B), which led 
to a low increase in signals responding to TNF-α stimulation when inoculated cells were 
less than 4000 per well in this test (Figure 1-4C). In the Beads Purification group, 
however, the increase in signals responding to TNF-α stimulation was rather high, even 
when the inoculated cells were the fewest 125 per well in this test (Figure 1-4C). The 
fold of increase tended to be constant when inoculated cells were more than 250 per 
well in this test (Figure 1-4C). Moreover, although diluting the medium with PBST (50% 
Medium group and 10% Medium group) could lower the background signal (Figure 1-
4A and B), the increases in signals responding to TNF-α stimulation were not improved 
compared to that of the Medium group when inoculated cells were less than 8000 per 










Figure 1-4. Examine the improved effects resulting from the purification strategy. 
TNF-α-stimulated NF-κB activation assay. (A) and (B) Measurement of 
bioluminescence from cells without or with TNF-α stimulation. Monoclonal HeLa cells 
stably transfected with the NF-κB -secNluc-FLAG gene were inoculated at different 
densities (0 to 8000 cells per well) in 24-well plates for 12 h. For TNF-α stimulation, 
50 ng/ml TNF-α was added for 12 h to induce the activation of the NF-κB signaling 
pathway (B). 100 μl of each cultured medium was subjected to magnetic bead 
purification, and the beads were resuspended in 100 μl of PBST. 100 μl of resuspended 
solution (Beads Purification), 100 μl of cultured medium (Medium), 50 and 10 μl of 
culture media that were supplemented with PBST to 100 μl (50% Medium and 10% 
Medium) were used to measure the emitted bioluminescence. The experiments were 
repeated three times with comparable results. (C) The ratios of RLU in groups with 
TNF-α stimulation to those in groups without TNF-α stimulation. The data shown are 
the means ± SDs of three independent experiments. 
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1.3.5 The p-cymene and shikonin had the significant effect on NF-κB pathway 
According to the previous reports29, 56), to inactivate or inhibit NF-κB pathway was 
considered as an effective way on tumor suppression. As an early phase transcription 
factor, NF-κB activation does not require the regulation of newly translated proteins. 
Therefore, it is possible to respond to the stimulation of harmful cells for the first time. 
The screening Traditional Chinese Medicine was selected on the basis of the decreased 
level of NF-κB. The 30 reagents were random selected from Traditional Chinese 
Medicine Extract Library. All of cell culture mediums in equal volume were collected 
and purified by the affinity purification strategy after drugs application. As shown in 
Fig. 1-5, the NF-κB expression was found to be decreased to 50% of control group by 
p-cymene (800 μM). In addition, shikonin (8 μM) was found to suppress NF-κB 
expression (70% inhibition vs. control group). Thus, these two compounds were used 




Figure 1-5. Examine the effect of NF-κB inhibition. The p-cymene and shikonin 
decreased the expression of NF-κB with extremely significant difference comparing 
with control group. The RLUs of mediums were utilized to evaluate the regulating 
effect of p-cymene and shikonin on NF-κB. *** P < 0.001. The data shown are the 
means ± SDs of three independent experiments. 
 
1.4 DISCUSSION 
 The application of secNluc can similarly be affected by the environment. In 
current study, the effects of three factors, such as conditioned medium, pH, serum and 




reactions using coelenterazine as the substrate. The pH of the conditioned medium is 
influenced by lactic acid, the by-product of cellular metabolism57). The pH of a normal 
mammalian cell culture medium may shift from an optimal pH of 7.4 to acidic pH of 
6.5 or below when cells are cultured at high density or are overgrown. The results 
showed that lower pH values significantly decreased the intensity of secNluc-catalyzed 
bioluminescence reactions. Serum is commonly used to support the growth of cells in 
culture. In current study, the existence of fetal bovine serum resulted in a degree of 
background signal, which significantly affected bioluminescence measurements in 
experiments with low cell count. This phenomenon was consistent with the previously 
reported observations that the presence of serum from different species in the assay 
medium resulted in significant increases in luminescent signal25, 58). Several medicines 
were employed in this study as reagents to evaluate the probable interferences of 
residual reagents on secNluc-catalyzed bioluminescence reactions. Some of these 
reagents greatly decreased the luminescence signal. Replacing culture medium with 
fresh medium to eliminate the reagents can certain minimize the interference. However, 
this process is not only laborious and time-consuming but may also weaken the 
experimental effects induced by reagents due to having to wait hours for the 
accumulation of the newly secreted luciferase without the administration of reagents. 
Overall, these results indicated that the factors pH, serum and residual reagents that 
exist in the environment in which secNluc remains after secretion could interfere 
bioluminescence reactions and/or result in background signal, thus affecting the 
precision and reliability of the secNluc reporter system. 
To resolve these issues, a simple affinity purification strategy was raised in which 
FLAG-tag was fused onto the C-terminus of secNluc using plasmid construction to 
produce a recombinant secNluc-FLAG protein. When applying the reporter system, 
anti-FLAG magnetic beads were used and a magnet to capture the recombinant proteins 
from cultured medium and transfer them directly into an optimal buffer before 
measuring light emission as usual. Herein, PBS (pH 7.4) supplemented with 0.03% (v/v) 
Triton X-100 was used as the reaction buffer, and stable light emission was more 
achievable in this buffer than in PBS or in media with or without FBS. Nevertheless, 
other optimal buffers can also be used with our strategy if they provide a stable pH and 
contribute to the production of low-background and stable light emission. The results 
showed that through the purification process, in addition to the optimal buffer resulted 
in accurate and reproducible measurements, the bioluminescence detection limit and 
the number of cells required for detection were greatly lowered due to dramatically 
decreased background signal, and meanwhile interference from residual reagents was 
eliminated. Because the magnetic beads themselves had no light output and had no 
obvious harm to the bioluminescence reactions based on the approximate 100% 
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recovery rate, they can be reserved in the reaction system. Thus, the simplest 
purification process could only comprise one time of mixture of medium and beads, 
and one or two times of collection of magnetic beads by magnet, lasting only a few 
minutes.  
Another advantage of this strategy is the enablement of enriching secNluc from 
conditioned medium or biological samples, such as blood or urine. The results showed 
that most of secNluc in volumes of 2.5 ml or 5 ml could be captured and enriched in a 
volume of 100 μl, which can be loaded into a well of 96-well plates for bioluminescence 
measurement. This enrichment would be necessary when secNluc concentrations are 
lower than the limit of detection, such as when enzymes are secreted from a few cells, 
when enzyme expression is driven by a weak promoter, or when secreted enzymes are 
diluted in a large volume of biological sample, such as blood or urine. 
The transcription activation assay is one of the most common applications of 
secreted luciferases. Herein, the TNF-α-stimulated NF-κB activation assay was used as 
a case study to examine the improved effects of our strategy. The results indicated that 
when the measured signals were weak, the increased fold of NF-κB activation induced 
by TNF-α stimulation using the bead purification strategy was far higher than those 
observed without the strategy. This improvement thus most likely represents the effect 
of TNF-α stimulation and may contribute to some investigations, such as the discovery 
of rare natural drugs. 
 
1.5 CONCLUSION 
In summary, a simple affinity purification strategy has been developed by which 
various optimizations of the application of the secNluc reporter system are 
simultaneously permitted. This strategy is not only suitable for the secNluc reporter 
system but also for reporter systems involving other secreted luciferases because the 
environmental interferences and enhancements from reaction buffer optimization and 
enzyme enrichment are basically common among all secreted luciferase reporter 
systems. The strategy will contribute to biomedical studies utilizing secreted luciferases, 
especially those requiring superior sensitivity, low background noise and high 
reproducibility. According to the experimental results, p-cymene and shikonin had the 
significant effect on NF-κB pathway. Therefore, the two reagents were investigated to 
address the antineoplastic actions in detail in the following experiments (see Chapters 
2 and 3). 
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CHAPTER 2 
Novel Antitumor Invasive Actions of p-Cymene by Decreasing MMP-
9/TIMP-1 Expression Ratio in Human Fibrosarcoma HT-1080 Cells 
 
2.1 INTRODUCTION 
At the end of chapter 1, several kinds of traditional Chinese medicine extracts were 
used to detect. One of the traditional Chinese medicine extracts, p-cymene (4-
isopropyltoluene) (Figure 2-1), was discovered that had antitumor activity. p-cymene is 
a natural monoterpene hydrocarbon occurring in the essential oil from the resin of 
Protium species36) and the root of Angelica archangelica37). Herbal medicine-derived 
terpenoids have been reported to exhibit not only antiproliferative but also antiinvasive 
activity against tumor cells in vivo 
and in vitro28). As a similar 
substance, current section 
focused on whether p-cymene has 
an antitumor invasive activity.  
In the present study, p-
cymene was investigated the 
effect on tumor invasiveness in 
vitro by monitoring the regulation 
of MMP and TIMP expression 
and the phosphorylation of extracellular signal receptor-activated kinase 1/2 (ERK1/2) 
and p38 mitogen-activated protein kinase (MAPK) in the human fibrosarcoma HT-1080 
cells. p-Cymene inhibited the production of proMMP-9, but not proMMP-2, and 
augmented TIMP-1 production in 12-O-tetradecanoylphorbol 13-acetate (TPA)-
stimulated HT-1080 cells. The results further demonstrated possible mechanisms by 
which p-cymene-mediated inhibition of proMMP-9 expression was due to the 
inhibition of constitutive and TPA-augmented phosphorylation of ERK1/2 and p38 
MAPK in HT-1080 cells. These results suggest that p-cymene is an attractive candidate 
with antitumor invasive activity due to the decrease of MMP-9/TIMP-1 expression ratio 
by inhibiting the ERK1/2 and p38 MAPK signal pathways. 
Figure 2-1. Chemical structure of p-cymene 
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2.2 MATERIALS AND METHODS 
2.2.1 Cell culture and treatment  
Human fibrosarcoma HT-1080 cells (Health Science Research Resources Bank, 
Osaka, Japan) were cultured in Eagle’s minimum essential medium (MEM) (Invitrogen, 
Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum (JRH Bioscience, 
Tokyo, Japan) and nonessential amino acids (Invitrogen). After reaching confluence, 
the cells were treated with p-cymene (ZeLang Medical Technology Co., NanJing, China) 
in the presence or absence of TPA (Sigma Chemical Co., St. Louis, MO) in MEM/0.2% 
(w/v) lactalbumin hydrolysate (Sigma Chemical, USA) for 24 h as previously described.  
2.2.2 Gelatin zymography 
The harvested culture medium (10 l) was subjected to SDS-polyacrylamide gel 
electrophoresis (PAGE) with 10% (w/v) acrylamide gel containing gelatin (0.6 mg/ml) 
(Becton Dickinson, Tokyo, Japan). The gel was washed with a washing buffer [50 mM 
Tris-HCl (pH 7.5)/0.15 M NaCl/10 mM CaCl2/1 M ZnCl2/0.1% (v/v) Triton X-100] 
to remove SDS and then incubated at 37˚C in an incubation buffer [50 mM Tris-HCl 
(pH 7.5)/0.15 M NaCl/10 mM CaCl2/1 M ZnCl2]. Thereafter, the gel was stained with 
Coomassie Brilliant Blue R-250 (Sigma Chemical, USA), and gelatinolytic activity was 
detected as unstained bands on a blue background. 
2.2.3 Western blotting 
The harvested culture medium (1 ml) was subjected to SDS-PAGE with 10% (w/v) 
acrylamide gel (for proMMP-9) and 12.5% (w/v) acrylamide gel (for TIMP-1). The 
proteins separated in the gel were electro transferred onto a nitrocellulose membrane 
and the membrane was reacted with sheep anti-(human proMMP-9) or anti-(human 
TIMP-1) antibody (graciously provided by Dr. H. Nagase, the Kennedy Institute of 
Rheumatology, University of Oxford, Oxford, UK), which was then complexed with 
horseradish peroxidase-conjugated goat anti- (sheep IgG) IgG. Immunoreactive 
proMMP-9 and TIMP-1 were visualized with enhanced chemiluminescence-Western-
blotting detection reagents (GE Healthcare Bio-Sciences, Tokyo, Japan) according to 
the manufacturer’s instructions. The relative amounts of the proteins were quantified 
by densitometric scanning using an Image Analyzer LAS-1000 Plus (GE Healthcare 
Bio-Sciences). 
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2.2.4 Quantitative RT-PCR analysis 
For the quantification of MMP-9 and TIMP-1 mRNA, total RNA was isolated from 
HT-1080 cells using ISOGEN (Nippon Gene, Toyama, Japan) and then subjected to 
reverse transcriptase reaction for the synthesis of cDNA using a Prime Script RT reagent 
Kit (Takara Bio, Shiga, Japan) according to the manufacturer’s instructions. Aliquots 
(an equivalent of 2.5 ng of total RNA) of the transcript were subjected to real-time PCR 
using SYBR Premix Ex Taq II (Takara Bio, Japan) and following specific primers: 
human MMP-9 (GeneBank: AF538844); CTATTTCTGCCAGGACCGCTTC 
(Forward) and CACCTGGTTCAACTCACTCCG (Reverse), human TIMP-1 
(GeneBank: BC000866); CTGACATCCGGTTCGTCTACACC (Forward) and 
GGGACCTGTGGAAGTATCCG (Reverse), and human glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (GeneBank: AJ005371); CATCCCTGCCTCTACTGGCG 
(Forward) and AGCTTCCCGTTCAGCTCAGG (Reverse). The amplification cycle 
was performed at 94˚C for 5 s and 60˚C for 30 s using a Thermal Cycler Dice Real 
Time System TP-800 (Takara Bio, Japan). The obtained threshold cycle (CT) value for 
MMP-9 and TIMP-1 was normalized by that for GAPDH, and the relative expression 
level was expressed as the mean value of the control as 1. 
2.2.5 Cell viability assay 
HT1080 cells were plated onto a 96-well multiplate with 1×104 cells/well, and then 
cultured for 24 h to achieve complete cell adhesion. The cells were treated for another 
24 h with or without p-cymene (200 - 800 μM) or an antitumor reagent, doxorubicin (1 
- 4 μM)59), and then cell viability was measured using a CellTiter-BlueTM Cell viability 
kit (Promega KK, Tokyo, Japan) according to the manufacturer’s instructions. 
2.2.6 Tumor invasion assay 
The tumor invasion assay was performed using MatrigelTM Invasion Chamber (24-
well, 8 mM) (Cosmo Bio Co., Tokyo, Japan) as described previously60). HT-1080 cells 
(4×104 cells) were added to insert chambers and then incubated at 37˚C for 1 h to 
achieve cell adhesion. The cells were treated for 24 h with p-cymene in the presence of 
TPA. After the treatment, invading cells were analyzed according to the manufacturer’s 
instructions. 
2.2.7 Analysis of ERK1/2 and p38 MAPK phosphorylation 
HT1080 cells were cultured in a 96-well multiplate with 3×104 cells/well, and then 
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cultured for 24 h to achieve complete cell adhesion. The cells were treated for 30 min 
with or without p-cymene in the presence or absence of TPA. After the treatment, 
phosphorylation of ERK1/2 (Thr202/Tyr204) and p38 MAPK (Thr180/Tyr182), and 
both proteins in HT-1080 cells were analyzed using RayBio® Cell-Based Human 
ERK1/2 (Thr202/Tyr204) and p38 MAPK (Thr180/Tyr182) Phosphorylation ELISA 
kits (RayBiotech Inc., Norcross, GA), respectively, according to the manufacturer’s 
instructions. 
2.2.8 Statistical analysis  
All data are expressed as the means ± standard deviations (SD) from at least three 
independent experiments. Data were analyzed by Student’s t-test; P < 0.05 was 
considered to indicate a statistically significant difference. 
 
2.3 RESULTS 
2.3.1 Inhibition of TPA-augmented MMP-9 expression by p-cymene in HT1080 
cells 
Since MMP-9 has been reported to participate in the invasion of malignant tumor 
cells, which are activated by tumor promotive reagents such as TPA60), the effects of p-
cymene on the expression of MMP-9 in TPA-stimulated HT-1080 cells were first 
examined. TPA was found to increase the production of proMMP-9 (10.8 ± 0.6 fold in 
mRNA level vs. untreated cells, P < 0.001), while the constitutive expression of 
proMMP-9 was negligible in HT-1080 cells (Figure 2-2A and B). In addition, the 
suppression of TPA-induced proMMP-9 production by p-cymene was found to be due 
to the inhibition of MMP-9 mRNA expression (38.4% inhibition at 600 M vs. TPA-
treated cells, P < 0.05) (Figure 2-2B). Furthermore, the constitutive gene expression of 
MMP-9 was not influenced in p-cymene-treated HT-1080 cells (Figure 2-2B). On the 
other hand, we have previously reported that HT-1080 cells constitutively express 
proMMP-2, and the proMMP-2 activation is facilitated by TPA60). As shown in Figure 
2-2A (upper panel), p-cymene did not alter the expression and activation of proMMP-
2 in HT-1080 cells treated with or without TPA. Thus, these results suggest for the first 
time that p-cymene transcriptionally suppresses the production of proMMP-9 in TPA-







Figure 2-2. Suppression of MMP-9 expression by p-cymene in TPA-stimulated 
HT1080 cells. HT-1080 cells were treated for 24 h with or without p-cymene (200 - 
600 M) in the presence or absence of TPA (10 nM). A: The harvested culture medium 
was subjected to gelatin zymography for proMMP-2 (upper panel) and proMMP-9 
(lower panel) as described in the Materials and Methods. iMMP-2, an intermediate form 
of MMP-2. aMMP-2, an active form of MMP-2. B: Isolated RNA (an equivalent of 2.5 
ng of total RNA) from the cells was subjected to the analysis of MMP-9 mRNA 
expression as described in the Materials and Methods. Data are shown as means ± SDs 
of three different experiments. ***, significantly different from untreated cells (Cont) 
(P < 0.001). #, significantly different from TPA (10 nM)-treated cells (P < 0.05). 
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2.3.2 The p-cymene increases the production and gene expression of TIMP-1 in 
TPA-stimulated HT1080 cells 
Since the enzymic activity of MMP has been reported to be controlled by not only 
their expression level but also TIMPs in vivo and in vitro34, 61, 62), the effects of p-cymene 
on the expression of TIMP-1 in TPA-stimulated HT-1080 cells were next examined. 
Figure 2-3A shows that p-cymene dose-dependently enhanced the TPA-augmented 
production of TIMP-1 but did not influence the constitutive level of TIMP-1 in HT-
1080 cells. In addition, the gene expression of TIMP-1 was further increased by 
cotreatment of TPA and p-cymene (1.3-fold increase at 600 M vs. TPA-treated cells, 
P < 0.05), while p-cymene alone did not influence TIMP-1 mRNA expression (Figure 
2-3B). Furthermore, the results confirmed that there was no change in cell viability in 
HT-1080 cells treated with up to 800 M of p-cymene, while an antitumor reagent, 
doxorubicin, dose-dependently decreased the cell viability (Figure 2-4). Therefore, 
these results suggest that, unlike in the case of MMP-9, p-cymene transcriptionally 
facilitates the production of TIMP-1 in TPA-stimulated HT-1080 cells. 
 
Figure 2-3. Enhancement of TIMP-1 expression by p-cymene in TPA-stimulated 
HT1080 cells. The harvested culture medium (A) and RNA (B) from the cells treated 
with or without p-cymene (200 - 600 M) and TPA (10 nM) were subjected to Western 
blotting and quantitative RT-PCR, respectively. Data are shown as means ± SDs of three 
different experiments. **, significantly different from untreated cells (Cont) (P < 0.01). 
#, significantly different from TPA (10 nM)-treated cells (P < 0.05). 
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Figure 2-4. No effect of p-cymene on cell viability in HT-1080 cells. HT1080 cells 
(1×104 cells/well) in a 96-well multiplate were treated for 24 h with p-cymene (0 - 800 
μM) or doxorubicin (1 - 4 M), and then cell viability was measured using a CellTiter-
BlueTM reagent as described in the Materials and Methods. Data are shown as means ± 
SDs of six individual wells. ***, significantly different from untreated cells (Cont)     
(P < 0.001). 
 
2.3.3 The p-cymene inhibits an in vitro invasive activity of HT-1080 cells  
Since it has been reported that HT-1080 cells exhibit the invasive activity due to 
the deregulation of the MMP/TIMP equilibrium in vitro and in vivo 60, 63), the effect of 
p-cymene on the invasiveness of HT-1080 cells was next examined using Matrigel-
coated insert chambers as previously reported60). As shown in Figure 2-5, TPA was 
found to increase the invasive activity of HT-1080 cells (2-fold vs. untreated cells). In 
addition, p-cymene dose-dependently inhibited the TPA-augmented invasiveness of 
HT-1080 (87% inhibition at 600 M). Taken together with our previous report that not 
only exogenous administration of TIMPs but also the relative augmented protein level 
of TIMP-1 against MMP-9 suppresses the invasiveness of HT-1080 cells60), it is 
suggested that p-cymene exerts an antiinvasive action by a mechanism in which the 
proteolytic activity of MMP may be inhibited in HT-1080 cells. 
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Figure 2-5. The p-cymene suppresses the invasiveness of HT-1080 cells in vitro.  
HT-1080 cells were treated with p-cymene (200 - 600 μM) in the presence or absence 
of TPA (10 nM) in the Matrigel invasion models and the invasive activity is analyzed 
as described in Materials and Methods. Data are shown as the means ± SDs of three 
individual chambers by taking untreated cells (Cont) as 1. ** and *** Significantly 
different from untreated cells (Cont) (P < 0.01 and 0.001, respectively). ###, 
Significantly different from TPA (10 nM)-treated cells (P < 0.001). 
 
2.3.4 Inhibition of ERK1/2 and p38 MAPK phosphorylation by p-cymene in 
HT1080 cells 
As the intracellular signal pathways of ERK1/2 and p38 MAPK have been reported 
to participate in the regulation of MMP-9 and TIMP-1 expression in various cell 
species64, 65), whether p-cymene may modulate the phosphorylation of ERK1/2 and p38 
MAPK in TPA-stimulated HT-1080 cells was examined. Figure 2-6 A and F shows that 
the TPA-augmented ERK1/2 phosphorylation (2.3 ± 0.1 fold vs. untreated cells, P < 
0.001) was inhibited by p-cymene (33.6 and 49.7% inhibition at 400 and 600 M, 
respectively, vs. TPA-treated cells, P < 0.001). In addition, the TPA-augmented p38 
MAPK phosphorylation (1.6 ± 0.1 fold vs. untreated cells, P < 0.001) was suppressed 
by p-cymene in a dose-dependent manner (29.6 and 60.1% inhibition at 400 and 600 
μM, respectively, vs. TPA-treated cells, P < 0.001) (Figures 2-6C, G). Furthermore, the 
basal levels of phosphorylated ERK1/2 and p38 were significantly decreased in p-
cymene at 600 μM (74.1 and 80.9% inhibition, respectively, vs. untreated cells, P < 
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0.001). However, there was no change in protein levels of ERK1/2, p38, and β-Actin in 
p-cymene and/or TPA treated HT-1080 cells (Figures 2-6B, D, E). Thus, these results 
suggest that p-cymene possesses dual inhibitory actions to ERK1/2 and p38 MAPK 
phosphorylation in HT-1080 cells. 
 
Figure 2-6. Inhibition of ERK1/2 and p38 MAPK phosphorylation by p-cymene in 
HT-1080 Cells. HT-1080 cells were treated for 30 min with p-cymene (200 - 600 μM) 
in the presence or absence of TPA (10 nM). Aliquots (30 μg protein) of harvested cell 
lysates were subjected to Western blotting for phosphorylated ERK1/2 (pERK1/2) (A) 
and p38 MAPK (p-p38) (C) using rabbit anti-phosphorylated ERK1/2 and p38 MAPK 
antibodies, respectively. Western blotting for ERK1/2 (B), p38 MAPK (p38) (D), and 
β-Actin (E) was similarly performed using their specific antibodies as described in 
Materials and Methods. The ratio of pERK1/2 (F) and p-p38 (G) against ERK1/2 and 
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p38, respectively, are shown as the means ± SDs. based on three independent 
experiments. ** and *** Significantly different from untreated cells (Cont) (P < 0.01 
and 0.001, respectively). ## and ### Significantly different from TPA-treated cells (P 
< 0.01 and 0.001, respectively). 
 
2.4 DISCUSSION 
p-Cymene has been reported to be a natural monoterpene in the essential oil of the 
resin of Protium species36) and the root of Angelica archangelica37), it is not reported 
that whether p-cymene exhibits antitumor invasive activity until now. In the present 
study, p-cymene was found that transcriptionally suppresses the production of 
proMMP-9 in TPA-stimulated HT-1080 cells. Furthermore, p-cymene was found to 
inhibit the TPA-enhanced invasiveness of HT-1080 cells.  
The enzymic activity of MMP is controlled by TIMPs, but the affinities of TIMPs 
vary for different MMP-TIMP pairs34). Since TIMP-1 has been reported to prefer to 
inhibit MMP-9 rather than MMP-234, 35), the augmentation of TIMP-1 expression has 
resulted in the inhibition of tumor metastasis by decreasing the overall MMP-9 activity 
in patients with prostate cancer62). In contrast, the deregulation of the MMP-9/TIMP-1 
equilibrium has facilitated the invasion of human MDA-MB-231 breast cancer cells66). 
In the present study, p-cymene was demonstrated that transcriptionally augments the 
production of TIMP-1 in TPA-stimulated HT-1080 cells, under which the invasiveness 
of HT-1080 cells was attenuated. Thus, these results suggested a possible mechanism 
in that the antitumor invasive activity of p-cymene includes not only the 
downregulation of MMP-9 production but also the upregulation of TIMP-1 production. 
It has been reported that different transcriptional factors and signal mediators 
divergently and complicatedly participate in the regulation of MMP-9 and TIMP-1 gene 
expression67). As the regulation of MMP-9 expression has been dependent on AP-1 
and/or NF-κB signal68, 69), results demonstrated that MMP-9 expression was augmented 
by TPA, which activates both signaling pathways70). In addition, it has been reported 
that the activation of the ERK1/2 and/or p38 MAPK pathways is involved in the 
upregulation of MMP-9 expression in some tumor cell lines such as human 
fibrosarcoma, oral squamous cell carcinoma, and cholangiocarcinoma62, 71, 72). The 
present chapter indicated that p-cymene suppressed the phosphorylation of ERK1/2 and 
p38 MAPK in TPA-treated HT-1080 cells, suggesting that the concomitant suppression 
of the ERK1/2 and p38 MAPK signal pathways by p-cymene at least partially results 
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in the downregulation of MMP-9 production. Moreover, as monoterpenoids including 
p-cymene have been reported to potentially inhibit the NF-κB signal pathway28, 30), the 
inhibition of NF-κB may be associated with the p-cymene-decreased expression of 
MMP-9 in TPA-stimulated HT-1080 cells. In Chapter 1, the experiment of screening 
target drugs by transcription factor reporter gene system also confirmed the viewpoint. 
Regarding the regulation of TIMP-1 expression, Zhang et al.73) has reported the 
augmentation of TIMP-1 production by inhibiting p38 MAPK phosphorylation by 
baicalein, a flavonoid from Scutellaria baicalensis, in human glioma U87MG cells, 
under which the production of proMMP-9 is suppressed. In contrast, Fields et al.74) has 
reported that a p38 selective small molecular inhibitor, SB203580, decreases the gene 
expression of TIMP-1 in IL-1-treated human astrocytes. On the other hand, we 
previously reported that the TPA-augmented TIMP-1 production is not suppressed by 
another selective p38 MAPK inhibitor, SB202190, but enhanced by a 
phosphatidylinositol 3-kinase (PI3K) inhibitor, LY-294002, in HT-1080 cells60). Thus, 
it is suggested that the involvement of p38 MAPK signaling in the regulation of TIMP-
1 expression is dependent on cell species and/or experimental conditions. Moreover, a 
PI3K signaling pathway may be associated with the p-cymene-enhancement of TIMP-
1 expression in TPA-stimulated HT-1080 cells. 
 
2.5 CONCLUSION 
The current chapter indicated that p-cymene inhibited in vitro invasiveness of HT-
1080 cells by transcriptionally not only suppressing MMP-9 expression but also 
enhancing TIMP-1 production. Furthermore, p-cymene decreased the TPA-augmented 
phosphorylation of ERK1/2 and p38 MAPK. Thus, p-cymene is likely to be an 
attractive candidate that exerts an antitumor invasive action by decreasing the MMP-




Shikonin Sensitizes A549 Cells to TRAIL-Induced Apoptosis through 
the JNK, STAT3, and AKT Pathways 
 
3.1 INTRODUCTION 
 Tumor necrosis factor-related apoptosis-inducing ligand, TRAIL, is a promising 
antitumor drug. It has reported that TRAIL induces apoptosis in cancer cells, however 
it is minimally cytotoxic to normal cells50, 51). However, intrinsic or acquired resistance 
to TRAIL-induced apoptosis has limited the further utilization of TRAIL in clinical 
trials.43). Therefore, seeking reagents that can sensitize resistant cancer cells to TRAIL-
induced apoptosis is greatly important. The present section investigated whether 
shikonin (Figure 3-1), a natural compound from the root of Lithospermum 
Erythrorhizon, can sensitize TRAIL-resistant cells to TRAIL-induced cytotoxicity. 
 
 
3.2 MATERIALS AND METHODS 
3.2.1 Chemicals and reagents 
Shikonin (Sigma, USA) was dissolved in dimethyl sulfoxide (DMSO) and stored 
as a stock solution (50 mM) in small aliquots at -20°C. Soluble recombinant human 
TRAIL was purchased from Peprotech. Primary antibodies specific to caspase-3, 
caspase-8, caspase-9, Mcl-1, Bcl-2, Bcl-xL, Bax, JNK, STAT3, Akt and the 
phosphorylated forms of JNK, STAT3 and Akt (Ser473) were purchased from Abcam. 
Primary antibody specific to β-Actin was obtained from Cell Signaling Technology, 
USA. 
Figure 3-1. Chemical structure of shikonin 
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3.2.2 Cell culture and treatment 
A549 human lung cancer cells were cultured in RPMI1640; HEK-293 human 
embryonic kidney cells were cultured in Eagle's minimum essential medium (EMEM). 
All types of media were supplemented with 10% heat-inactivated fetal bovine serum. 
Cultures were maintained at 37˚C in a humidified atmosphere of 5% CO2/95% air75). 
3.2.3 Cell viability assay 
    A549 and HEK-293 cells were seeded into two sets of 96-well plates in triplicate 
(2104 cells/ 100 μl/well). After incubation for 12 h, filter-sterilized shikonin was added 
to the culture medium in one plate at concentrations of 0, 1, 2, 4, 6 and 8 μM, and 
TRAIL (50 ng/ml or 5 ng/ml) was added to the culture medium in another plate with 
the appropriate controls. After incubation for 12 h, the cell viability in the plate treated 
with only sTRAIL was assessed by a Cell Counting Kit-8 (CCK8) assay75); the 
shikonin-pretreated plate was then treated with TRAIL (50 ng/ml or 5 ng/ml) for 
another 12 h, and the cell viability was determined by a CCK8 assay. Furthermore, a 
long-term cytotoxicity experiment was performed as follows: shikonin (4 μM), alone 
or supplemented with TRAIL (50 ng/ml), was added to A549 and HEK-293 cells. Cell 
viability was detected over 96 h at 24 h intervals via a CCK8 assay. Moreover, the pan-
caspase inhibitor Z-VAD-FMK (Sigma, USA) was employed for the assessment of the 
effects of shikonin and TRAIL on A549 cells. After pretreatment with Z-VAD-FMK 
(50 μM) for 60 min, shikonin and TRAIL were added. 
3.2.4 Annexin V/PI assay 
Early indicators of apoptosis were detected by using an annexin V/PI binding kit 
(Biolegend, USA) and a flow cytometer (Accuri C6, BD Biosciences, USA). In brief, 
A549 cells were seeded in 6-well plates (4105 cells/well) and treated with shikonin (4 
μM) or TRAIL (50 ng/ml) for 12 h. TRAIL-treated cells were collected by 
trypsinization and then analyzed following the protocol. Flow cytometry was 
performed within 1 h of cell harvesting. After pretreatment with shikonin (4 μM) for 12 
h, A549 cells were then incubated in the presence or absence of 50 ng/ml TRAIL for 
another 12 h. Then, all the cells were collected and analyzed as above.   
3.2.5 Western blotting 
A549 cells were seeded and incubated overnight in a 10 mm culture dish 
(2.5106/well). Next, shikonin (4 μM) and TRAIL (50 ng/ml) were added to the culture 
medium. After incubation for 12 h, the TRAIL-treated A549 cells were harvested, and 
whole cell lysates were prepared with lysis buffer. The shikonin-treated A549 cells were 
then treated or not treated with 50 ng/ml TRAIL for another 12 h, after which whole 
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cell lysates were prepared76). 
3.2.6 Statistical analysis 
The data are expressed as the means ± standard deviations (SD) and were analyzed 
by Student's t-test using SPSS software to determine the significance of differences 
between groups. P < 0.05 was considered statistically significant 
 
3.3 RESULTS 
3.3.1 Shikonin enhances TRAIL-induced cytotoxicity 
After treatment with TRAIL alone, the viability of TRAIL-resistant A549 cells was 
almost 95%. However, in cells pretreated with shikonin, TRAIL noticeably decreased 
the viability of A549 cells over time. A synergistic effect of shikonin and TRAIL on 
A549 cell killing was observed (Figure 3-2A). In addition, the cytotoxicity of shikonin 
and TRAIL in the normal human renal cell line HEK-293 was assessed. Surprisingly, 
although shikonin was cytotoxic to the human lung cancer cell line A549, it was almost 
nontoxic to HEK-293 cells. Moreover, shikonin and TRAIL cotreatment was not 
cytotoxic to HEK-293 cells (Figure 3-2B). The long-term cytotoxicity experiment 
demonstrated that the concentrations of shikonin and TRAIL were safe in normal cells 
(Figure 3-2C). Z-VAD-FMK, the caspase inhibitor, significantly increased cell viability 
in the groups cotreated with shikonin and TRAIL (Figure 3-2D). Nevertheless, Z-VAD-
FMK did not noticeably influence cell viability when shikonin and TRAIL were 













Figure 3-2 Effect of shikonin on TRAIL-induced cell cytotoxicity. The viability of 
(A) A549 and (B) HEK-293 cells after treatment were determined by CCK8 assay. Cells 
were pretreated with different concentrations of shikonin for 12 h and then further 
incubated in the presence or absence of TRAIL (50 ng/ml) for another 12 h. C. In the 
long-term cytotoxicity experiment, HEK-293 was not influenced by shikonin and 
TRAIL in 96h, however A549 shown the significant inhibited by shikonin especially 
with TRAIL cotreatment. D. These data shown the efficacy of shikonin (4μM) and 
TRAIL (50ng/ml) on A549 cells pretreated with Z-VAD-FMK (50μM). The data were 
presented as the means ± SDs of at least three independent experiments, * P < 0.05; 










3.3.2 Synergistic effect of shikonin and TRAIL on apoptosis induction in A549 
After the cell viability experiment, a concentration of shikonin (4 μM) was selected 
for subsequent experiments because this concentration demonstrated the most apparent 
synergistic effect on TRAIL-induced cytotoxicity in A549 cells. To determine whether 
shikonin enhanced TRAIL-induced cytotoxicity via apoptosis, apoptosis was quantified 
by annexin V-PI flow cytometry. After pretreatment with shikonin (4 μM) for 12 h 
followed by treatment with 50 ng/ml TRAIL for 12 h, the adherent and suspended A549 
cells were collected for flow cytometric analysis. The results indicated that treatment 
with either shikonin (4 μM) or TRAIL (50 ng/ml) alone induced an apoptosis rate of 
only 3.4% or 6.1%, respectively, while cotreatment with shikonin and TRAIL caused 
an apoptosis rate of 43.2%; most of the apoptotic cells were in early apoptosis stages 
(Figure 3-3A). Morphological changes in A549 cells after the treatments described 
above were observed by microscopy; as the arrows in the figure 3-3B, cellular 
suspension, shrinkage and blebbing were observed after cotreatment with shikonin and 
TRAIL, whereas no obvious morphological changes were observed in the groups 
treated with only shikonin or TRAIL. In addition, the proliferation of A549 cells was 
inhibited after shikonin treatment. Caspase-3, -8 and -9 expression, the hallmarks of 
cells undergoing apoptosis, was also investigated by Western blotting to further confirm 
the apoptosis phenomenon. The levels of both pro-caspase-3 and pro-caspase-8 were 
appreciably decreased in A549 cells after cotreatment with shikonin and TRAIL, while 
treatment with either shikonin or TRAIL alone had almost no effect on caspase-3 or 
caspase-8 expression. The Western blotting results showed that cotreatment with 
shikonin and TRAIL did not activate caspase-9 (Figure 3-3C, D, E). Taken together, 
our results indicated that TRAIL-induced apoptosis in A549 cells was augmented after 














































Figure 3-3 Synergistic effect of shikonin and TRAIL on apoptosis induction in TRAIL-
resistant A549 cells. (A) A549 cells were pretreated with shikonin (4 μM) for 12 h and 
then exposed to 50 ng/ml for another 12 h. Cells were harvested to quantify the 
induction of apoptosis by Annexin V/PI staining and flow cytometry. The data in each 
plot indicated the percentage of apoptotic cells. (B) Cell morphology was analyzed 
under an inverted microscope (magnification100) after the same treatment used in (A). 
(C, D, E) Whole cell lysates were prepared after using the same treatment mentioned 
above and analyzed by Western blotting using antibodies specific to caspase-3, -8 and 
-9. β-Actin was used as the loading control. The data were presented as the means ± 
SDs from at least three independent experiments, and significant differences between 
control group and the other groups in each item respectively were shown as * P < 0.05, 
** P < 0.01 and *** P < 0.001. S + T: shikonin + TRAIL. 
 
3.3.3 Shikonin potentiates TRAIL-induced apoptosis by inhibiting antiapoptotic 
proteins 
Next, the enhancement mechanisms of TRAIL-induced apoptosis by shikonin was 
explored. Various antiapoptotic or proapoptotic proteins regulate TRAIL-induced 
apoptosis, so the antiapoptotic proteins Mcl-1, Bcl-2 and Bcl-xL and the proapoptotic 
protein Bax were investigated by Western blotting. Cotreatment with shikonin and 
TRAIL inhibited the expression of the antiapoptotic proteins Mcl-1, Bcl-2 and Bcl-xL, 
while the combination treatment had no effect on the Bax expression (Fig 3-4). Thus, 
these results indicated that the downregulation of antiapoptotic proteins was the 







Figure 3-4 Effect of shikonin and TRAIL on antiapoptotic and proapoptotic 
protein expression in A549 cells. (A) A549 cells were pretreated with shikonin (4 μM) 
for 12 h and then incubated with TRAIL (50 ng/ml) for another 12 h. Whole cell lysates 
were prepared and analyzed by Western blotting using the indicated antibodies. β-Actin 
was used as the loading control. (B) The data were presented as the means ± SDs of at 
least three independent experiments, and significant differences between control group 
and the other groups in each item respectively were shown as ** P < 0.01 and *** P < 







3.3.4 JNK, STAT3 and AKT pathways were involved in shikonin-mediated TRAIL 
sensitization 
Other signaling pathways were further investigated, including the JNK, STAT3 and 
AKT pathways77), which were reported to be responsible for resistance to TRAIL. In 
cells pretreated with shikonin (4 μM) for 12 h followed by treatment with TRAIL (50 
ng/ml) for 12 h. Western blotting showed that shikonin upregulated the phosphorylation 
of JNK (p-JNK); more specifically, the expression of p-JNK was higher after 
cotreatment than after either treatment alone. On the other hand, shikonin 
downregulated the phosphorylation of STAT3 and AKT, and downregulation was more 
apparent after cotreatment with shikonin and TRAIL (Fig 3-5). Therefore, upregulation 
of p-JNK, suppression of p-STAT3 and p-AKT might be the sensitization mechanisms 











Figure 3-5 Activation of JNK and inhibition of STAT3 and AKT are associated 
with the induction of apoptosis by shikonin and TRAIL cotreatment in A549 cells. 
(A) The expression of total and phosphorylated forms of JNK, STAT3 and AKT were 
assessed using the corresponding antibodies via Western blotting. (B) The data were 
presented as the means ± SDs of at least three independent experiments, and significant 
differences between control group and the other groups were shown as * P < 0.05, ** 
P < 0.01 and *** P < 0.001. S + T: shikonin + TRAIL. 
 
3.4 DISSCUSSION 
Shikonin, a natural product isolated from the Chinese herbal plant Lithospermum 
Erythrorhizon, can sensitize several types of TRAIL-resistant cells to TRAIL-induced 
cytotoxicity. Viability was employed to evaluate in A549 and HEK-293 which were 
tested after cotreating with shikonin followed by TRAIL, compared with shikonin or 
TRAIL treatment alone. Apparently, a synergistic effect of shikonin and TRAIL on 
cytotoxicity was observed in TRAIL-resistant A549 cell, but not in normal HEK-293 
cell. It was found that shikonin (1-8 μM) alone or combined with TRAIL caused almost 
no cytotoxicity in the HEK-293 (Fig. 3-2A, B). 96h long time drug effect test indicated 
that the TRAIL and shikonin still had no cytotoxicity on HEK-293. On the contrary, the 
cytotoxicity has been shown obviously on A549. This result is in accordance with the 
report by Gong K et al43).  
Cysteinyl aspartate specific protease, or caspase, is a kind of proteolytic enzyme 
closely related to apoptosis. In apoptosis, the caspase family has two main functions: 
apoptosis initiation and apoptosis execution78, 81). The activated apoptosis initiation 
caspase molecule, which is cleaved and activated by external protein signals, activates 
the apoptosis-executing caspase molecule and hydrolyzes the target protein, leading to 
programmed cell death. Therefore, cleaved caspases were investigated, and the results 
demonstrated that the shikonin + TRAIL drug combination promoted caspase-8 and 
caspase-3 cleavage. Caspase-8, an apoptosis initiation molecule, undergoes self-
activation through oligomerization and activates downstream caspases, resulting in 
irreversible apoptosis79, 80). Thus, caspase-8 is the key protease in the death receptor 
pathway.  
When cells are stimulated by apoptotic factors, TRAIL binds the corresponding 
death receptor, causing the activation of caspase-8. Then, the downstream caspases can 
induce a "waterfall" activation process. This action leads to the transfer of the apoptosis 
signal from the nondependent mitochondrial pathway to the mitochondrial pathway, 
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linking the death receptor pathway with the mitochondrial pathway and amplifying the 
apoptotic signal77, 82). The observation of cleaved caspase-3, -8, and -9 was consistent 
with this theory. Moreover, the pan-caspase inhibitor enhanced cell viability in the 
shikonin + TRAIL group, proving that shikonin increased the apoptosis-inducing ability 
of TRAIL via the caspase pathway. 
In studying the mechanisms by which shikonin sensitizes cells to TRAIL-induced 
cytotoxicity, I found that treatment with shikonin followed by TRAIL inhibited the 
expression of antiapoptotic proteins in the Bcl-2 family: Mcl-1, Bcl-2 and Bcl-xL (Fig. 
3-4). In addition, JNK was activated, and STAT3 and AKT were inhibited. STAT3 is a 
cytoplasmic transcription factor that plays a critical role in the regulation of genes 
involved in cell proliferation and survival. Activated STAT3 has been reported to 
prevent tumor cells apoptosis by regulating associated genes, such as Bcl-2, Bcl-xL and 
Fas83, 84). Furthermore, STAT3 inhibition has been shown to prevent cell proliferation 
and induce apoptosis in several cancer cell types85-87). AKT is a protein kinase involved 
in multiple cellular processes, including cell survival, proliferation, metabolism, 
apoptosis and tumorigenesis. AKT suppression has been reported to inhibit 
proliferation and induce apoptosis in multiple tumor cells56, 88, 89). As the Fig. 3-3C 
shows, I observed a phenomenon of growth or proliferation inhibition in the shikonin-
treated group; this result might be related to the decreases in activated STAT3 and JNK. 
Among above three pathways, the inhibition of STAT3 and AKT pathways is generally 
considered beneficial for promoting tumor killing. However, the function of the JNK 
pathway in tumor killing is controversial75, 90). Some findings support the pro-oncogenic 
function of JNK, while others suggest that JNK is a tumor suppressor. The results of 
the present study support the latter view. 
 
3.5 CONCLUSION 
The results indicated that the viability of A549, which was resistant to TRAIL, was 
dramatically decreased after the cotreatment of shikonin following TRAIL. 
Cotreatment with shikonin and TRAIL activated the JNK pathway, inhibited the STAT3 
and AKT pathways, and downregulated the expression of the antiapoptotic proteins 
Mcl-1, Bcl-2, and Bcl-xL. Shikonin can sensitize resistant cancer cells to TRAIL-
induced cytotoxicity via the JNK, STAT3, and AKT pathways and the downregulation 
of antiapoptotic proteins. 
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GENERAL DISCUSSION AND CONCLUSION 
Secreted luciferases have significant advantages over intracellular luciferases as 
reporters in non-disruptive reporter gene assays, real-time monitoring and high-
throughput drug screening19-24). The benefits of secreted luciferases also include their 
applications in ex vivo monitoring of in vivo biological processes and in providing dual 
luciferase assays together with intracellular luciferases3, 91, 92). Nevertheless, secreted 
luciferases have several disadvantages25), as they are inevitably mixed with components 
of conditioned medium surrounding test cells or biological samples, such as blood or 
urine26). These mixtures may affect the results of luciferase-catalyzed bioluminescence 
reactions, especially in experiments requiring superior sensitivity, low background 
noise and high reproducibility. Therefore, eliminating interfering components and 
transferring luciferase-catalyzed bioluminescence reactions into an optimized buffer 
should lead to more qualified results. 
As a secreted luciferase, secNluc was newly developed for bioluminescence 
application. Compared with other secreted luciferases such as Gaussia, Metridia and 
Cypridina luciferases, Nano-luciferase possesses the advantages of high structural 
stability, long half-life, and glow-type kinetics together with high light emission 
intensity, and thus would become one of the most valuable tools for bioluminescence 
assays12, 13). The luciferase reporter system is nowadays accepted as a favored and 
valuable tool for high-throughput drug screening 9). Reliability in high-throughput 
screening requires the maximum parallelization of the detection process. In the 
application of the luciferase reporter system, however, the parallelism may be easily 
affected by the rapid decay of the bioluminescence signal, the interfering components 
existing in samples, such as serum or residual reagents, and so on. The strategy 
developed in this study presents an optimized application of secreted luciferase-
catalyzed bioluminescence analysis by eliminating the interference of reagents and 
residual substances and providing an optimized and uniform environment for 
bioluminescence reactions, and thus may benefit the high-throughput drug screening 
using the luciferase reporter system. The detection efficiency is significantly improved, 
and the parallelism of test results is more stable. 
Furimazine was manufactured by Promega as a modified substrate for Nano-
luciferase, including secNluc12). It gives a higher initial bioluminescence signal and a 
much slower signal decay compared to coelenterazine. However, regardless of its far 
more expensive cost, enzyme-catalyzed bioluminescence reactions using this substrate 
are also affected by lower pH conditions12), and meanwhile background signal caused 
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by serum and interference brought from residual reagents cannot also be ignored. 
Therefore, the purification strategy presented herein may also be suitable for secNluc 
reporter systems using furimazine. 
According to the established high-sensitivity method, two monomers with potential 
antitumor activity had been screened out from Traditional Chinese Medicine Extract 
Library. In the present study, NF-κB transcription factor reporter gene system was 
employed to preliminary screen the reagents that could inhibit NF-κB. Activated NF-
κB induces the transcription of target genes and the activation of multiple signals. 
Inhibition of NF-κB activity has been reported to be conducive to tumor elimination28, 
29). 
Concerning p-cymene, monoterpenes have been identified as the major 
constituents of the essential oil from medicinal herbs, which are extensively used in 
traditional Chinese medicine28). For instance, Aucubin, a monoterpenoid based 
compound, has been reported to inhibit the proliferation of human non-small cell lung 
cancer A549 cells through the augmentation of p53 expression and the activation of the 
Fas ligand-mediated apoptosis pathway93). In addition, it has been reported that d-
limonene has antiangiogenic and proapoptotic effects on human gastric cancer BGC-
823 cells implanted into nude mice, which thereby inhibits tumor metastasis in vivo94). 
Taken together with previous reports that the augmented expression of MMP-9 is 
implicated in the metastatic phenotype of many cancers in vivo and in vitro95, 96), p-
cymene is likely to be useful for the prevention of tumor invasion and metastasis. 
According to previous reports, the results of this study have been supported. 
In the study of shikonin, TRAIL, owning to its action to selectively destroy tumor 
cells while minimally cytotoxic to normal cells, is regarded as one of the most 
promising cancer therapeutic drugs97). However, drug resistance substantially hinders 
the efficacy of chemical medicines, and resistance to TRAIL has been reported98). Some 
patients may develop resistance to TRAIL99, 100), which limits the utilization of TRAIL 
as a therapeutic reagent in cancer. The mechanism of resistance to TRAIL is not 
completely understood, but may be related to deregulation the components in TRAIL-
induced apoptotic pathway. Deregulation of TRAIL receptors, including 
downregulation of the death receptors DR4 and DR5 and overexpression of the decoy 
receptors DcR1 and DcR2, at the membrane level and deregulation of apoptosis-related 
proteins, including overexpression of the antiapoptotic proteins Bcl-2, Bcl-xL, Mcl-1 
and downregulation of the proapoptotic proteins Bax, Bid, and Bak, at the intracellular 
level, are responsible for resistance to TRAIL-induced apoptosis. On the other hand, 
activation of antiapoptotic pathways, such as NF-κB, MAPKs, PI3K/AKT, and STAT 
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pathways, might also confer resistance to TRAIL-induced apoptosis101). In addition, 
several reports indicated that shikonin may have an activity to selectively kill tumor 
cells46, 53) because it can induce intrinsic reactive oxygen species (ROS) upregulation29, 
102). In addition, compared with normal cells, tumor cells might be exposed to oxidative 
stress with higher ROS levels due to an imbalanced redox status103-105). Thus, tumor 
cells are likely to be vulnerable to reagents that increase ROS production, while normal 
cells are not104). Further experiments need to clarify this hypothesis. 
In conclusion, the present study demonstrated for the first time that a simple affinity 
purification strategy for screening of bioactive compounds from Chinese herbal extracts 
is developed by simultaneously the optimized application of the secNluc reporter 
system. This strategy is especially suitable for low abundance and high sensitivity and 
repeatable sample. In addition, the efficiency and simplicity of the strategy are likely to 
be applicable in various ways. Furthermore, the screening with the affinity purification 
strategy has provided two neoplastic candidates: p-cymene and shikonin, from Chinese 
herbal extracts. The former has shown the antitumor invasive activities by 
transcriptionally suppression of MMP-9 production and enhancement of TIMP-1 
production due to the inhibition of ERK1/2 and p38MAPK phosphorylation in HT-1080 
cells. The latter has exhibited the growth inhibitory activities against tumor cells by 
enhancing TRAIL-induced apoptosis, by mechanisms which the activation of JNK 
pathway and the inhibition of STAT3 and AKT ones result in a decrease in the level of 
antiapoptotic molecules in A549 cells. Finally, these findings could contribute to the 
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